JPWO2023056369A5 - - Google Patents

Info

Publication number
JPWO2023056369A5
JPWO2023056369A5 JP2024519447A JP2024519447A JPWO2023056369A5 JP WO2023056369 A5 JPWO2023056369 A5 JP WO2023056369A5 JP 2024519447 A JP2024519447 A JP 2024519447A JP 2024519447 A JP2024519447 A JP 2024519447A JP WO2023056369 A5 JPWO2023056369 A5 JP WO2023056369A5
Authority
JP
Japan
Prior art keywords
composition
tau
seq
conjugate
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538615A5 (https=
JP2024538615A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077279 external-priority patent/WO2023056369A1/en
Publication of JP2024538615A publication Critical patent/JP2024538615A/ja
Publication of JP2024538615A5 publication Critical patent/JP2024538615A5/ja
Publication of JPWO2023056369A5 publication Critical patent/JPWO2023056369A5/ja
Pending legal-status Critical Current

Links

JP2024519447A 2021-09-29 2022-09-29 タウホスホペプチドコンジュゲートの安全な投与の方法 Pending JP2024538615A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261793P 2021-09-29 2021-09-29
US63/261,793 2021-09-29
PCT/US2022/077279 WO2023056369A1 (en) 2021-09-29 2022-09-29 Method of safe administration of tau phosphopeptide conjugate

Publications (3)

Publication Number Publication Date
JP2024538615A JP2024538615A (ja) 2024-10-23
JP2024538615A5 JP2024538615A5 (https=) 2025-10-09
JPWO2023056369A5 true JPWO2023056369A5 (https=) 2025-10-09

Family

ID=85783654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519447A Pending JP2024538615A (ja) 2021-09-29 2022-09-29 タウホスホペプチドコンジュゲートの安全な投与の方法

Country Status (9)

Country Link
US (1) US20250049900A1 (https=)
EP (1) EP4408864A4 (https=)
JP (1) JP2024538615A (https=)
KR (1) KR20240082368A (https=)
CN (1) CN118613496A (https=)
AU (1) AU2022356435A1 (https=)
CA (1) CA3233247A1 (https=)
MX (1) MX2024003775A (https=)
WO (1) WO2023056369A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598356A (en) * 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
KR102710762B1 (ko) * 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
EA202192891A1 (ru) * 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин

Similar Documents

Publication Publication Date Title
US9095536B2 (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
AU2011200170C1 (en) Alzheimer's disease treatment method
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
US20150093432A1 (en) Composition
JP2023175708A5 (https=)
US20100028353A1 (en) Anti-amyloid immunogenic compositions, methods and uses
AU2021345451A1 (en) Beta-amyloid vaccine for the treatment of alzheimer's disease
EP2659908A1 (en) Compositions
CN117751132A (zh) 用于治疗阿尔兹海默氏病的tau疫苗
JPH05506234A (ja) ワクチン組成物
JPWO2023056369A5 (https=)
EP2106802A1 (en) Modified peptides as synthetic vaccines in amyloid-associated disease
US12121561B1 (en) Composition for treating or preventing insulin resistance
JPWO2023019241A5 (https=)
CN119894531A (zh) Tau肽免疫原构建体
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease
HK1171460A (en) Beta immunogenic peptide carrier conjugates and methods of producing the same
AU2011226926A1 (en) Alzheimer's disease treatment method
HK1169831A (en) A beta immunogenic peptide carrier conjugates and methods of producing same